Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...

In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains ...

Gain insight into how the MATTERHORN trial’s results across PD-L1 subgroups could expand access to immunotherapy and reshape ...

Learn how increasing system complexity and patient-facing technologies are creating new burdens for clinical trial sites—and ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...

Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site ...

In today’s ACT Brief, we explore how AstraZeneca is redefining gastric cancer care through the MATTERHORN trial, Phesi’s Gen Li shares how AI and patient data are advancing global trial equity, and ...

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

Learn how perioperative immunotherapy with Imfinzi is addressing long-standing unmet needs in gastric and GEJ cancers and paving the way for a new standard of care.

On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...